...
首页> 外文期刊>Tumour biology : >Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients
【24h】

Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients

机译:肿瘤标志物AFP和PIVKA-II在中国肝细胞癌患者中的诊断性能

获取原文
           

摘要

Alpha-fetoprotein is an effective biomarker as an aid in hepatocellular carcinoma detection in many countries. However, alpha-fetoprotein has its limitations, especially in early hepatocellular carcinoma diagnosis. Protein induced by vitamin K absence or antagonist-II is another biomarker that is used for hepatocellular carcinoma detection. The aim of this study is to compare the diagnostic performance of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II alone and in combination to explore improving biomarker performance as an aid in early hepatocellular carcinoma detection. In this study a total of 582 serum samples including 132 hepatocellular carcinoma patients, 250 non-hepatocellular carcinoma patients, and 200 healthy volunteers were collected. Alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II levels were measured by both chemiluminescent enzyme immunoassay on LUMIPULSE platform and by chemiluminescent microparticle immunoassay on ARCHITECT platform. Receiver operation characteristic curve analyses were performed for each biomarker and in combination. The results showed that Alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in combination have shown higher area under the curve compared to alpha-fetoprotein alone for diagnosis in whole patients (0.906 vs 0.870) in hepatocellular carcinoma early-stage patients (0.809 vs 0.77) and in hepatitis B virus–related hepatocellular carcinoma patients (0.851 vs 0.788) with ARCHITECT platform. Protein induced by vitamin K absence or antagonist-II showed higher area under the curve than alpha-fetoprotein for diagnosis of hepatitis B virus–related hepatocellular carcinoma patients (0.901 vs 0.788).We conclude that Combining alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II may improve the diagnostic value for early detection of hepatocellular carcinoma. Protein induced by vitamin K absence or antagonist-II performs better than alpha-fetoprotein in diagnosis of hepatitis B virus–related hepatocellular carcinoma patients.
机译:甲胎蛋白是一种有效的生物标志物,在许多国家可以作为肝细胞癌检测的辅助工具。但是,甲胎蛋白有其局限性,特别是在早期肝细胞癌的诊断中。由缺乏维生素K或拮抗剂II诱导的蛋白质是用于肝细胞癌检测的另一种生物标记。这项研究的目的是比较甲胎蛋白和维生素K缺乏或单独使用拮抗剂II诱导的蛋白的诊断性能,并结合探索改善生物标志物的性能作为早期肝细胞癌检测的辅助手段。在这项研究中,总共收集了582个血清样本,包括132例肝细胞癌患者,250例非肝细胞癌患者和200名健康志愿者。通过LUMIPULSE平台上的化学发光酶免疫分析和ARCHITECT平台上的化学发光微粒免疫分析,可以测量甲胎蛋白和由维生素K缺乏或拮抗剂II水平诱导的蛋白质。对每种生物标志物及其组合进行受体操作特征曲线分析。结果表明,与α-甲胎蛋白相比,α-甲胎蛋白和由缺乏维生素K或拮抗剂-II联合诱导的蛋白在整个肝癌早期患者中的诊断曲线下面积更大(0.906 vs.0.870)。 (0.809 vs 0.77)和使用ARCHITECT平台的与乙肝病毒相关的肝细胞癌患者(0.851 vs 0.788)。由维生素K缺乏或拮抗剂II诱导的蛋白在诊断乙型肝炎病毒相关肝细胞癌患者中的曲线下面积比甲胎蛋白高(0.901 vs 0.788)。我们得出结论,将甲胎蛋白与维生素K诱导的蛋白结合使用缺乏或拮抗剂-II可能会提高对肝细胞癌早期检测的诊断价值。由维生素K缺乏或拮抗剂II诱导的蛋白质在诊断乙型肝炎病毒相关的肝细胞癌患者中的表现优于甲胎蛋白。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号